Company Performance - As of August 1, 2025, Longshen Rongfa (300534) closed at 11.28 CNY, up 4.16% with a turnover rate of 16.28% and a trading volume of 491,600 shares, amounting to 554 million CNY [1] - The latest quarterly report shows total revenue of 289 million CNY, a year-on-year increase of 13.52%, and a net profit attributable to shareholders of 24.21 million CNY, up 9.18% year-on-year [1] - The company's non-recurring net profit reached 26.92 million CNY, reflecting a year-on-year growth of 26.88% [1] - Financial ratios include a current ratio of 1.430, a quick ratio of 1.160, and a debt-to-asset ratio of 46.50% [1] Capital Flow - On the reporting day, the net inflow of main funds was 34.93 million CNY, accounting for 6.3% of the total transaction amount [1] - Large orders saw a net inflow of 34.64 million CNY, representing 6.25% of the transaction amount, while small orders experienced a net outflow of 62.55 million CNY, which is 11.28% of the transaction amount [1] Company Background - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. was established in 2002 and is located in Lanzhou, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 303.345 million CNY and has made investments in five enterprises, participated in 2,052 bidding projects, and holds 17 trademarks and 46 patents [2]
陇神戎发（300534）8月1日主力资金净流入3493.46万元